---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-008508"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:10:09.802654+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13

## Summary
- Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
- AstraZeneca's motion to dismiss Puma as plaintiff granted on standing grounds; Puma remains counterclaim-defendant.
- Puma retains contractual rights under Pfizer license to seek monetary damages in the case.
- Jury trial scheduled for May 13, 2024 in Delaware federal court.
- Suit alleges Tagrisso infringes patents licensed exclusively to Puma; Wyeth continues as co-plaintiff.

## SEC filing metadata
- accession: 0001437749-24-008508
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774924008508/0001437749-24-008508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774924008508/pbyi20240319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-008508
- JSON: https://secwatch.observer/filing/0001437749-24-008508.json
- Plain text: https://secwatch.observer/filing/0001437749-24-008508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.